Trial seeks right dose to shield tiniest babies from harmful inflammation
NCT ID NCT07254000
Summary
This study aims to find the safest and most effective dose of a medication called anakinra for very premature babies. It will involve 24 infants born between 24 and 28 weeks of pregnancy. Researchers will test three different doses given by IV and also explore giving it as a shot under the skin to see how the baby's body processes the drug and if it helps control inflammation linked to long-term health problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Monash Children's Hospital
RECRUITINGClayton, Victoria, 3168, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Starship Children's Hospital
NOT_YET_RECRUITINGGrafton, Auckland, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.